Bromocriptin

Reading File

Searching for comprehensive information on bromocriptine — pharmacology, clinical uses, dosing, and adverse effects.

search_medical_text

bromocriptine mechanism of action pharmacology

Harrison's Principles of Internal Medicine, Twenty First Edition

Page 10614

search_medical_text

bromocriptine clinical uses indications dosing adverse effects

Developing a Diabetes Mellitus Comprehensive Care Plan 2022 Update

Page 57

GradeResponse

Here is a comprehensive overview of bromocriptine:

Bromocriptine

Drug Class & Mechanism

Bromocriptine mesylate is an ergot alkaloid and dopamine receptor agonist (primarily D2 receptors). Its actions depend on the target tissue:

Pituitary: Activates dopamine receptors on lactotroph cells → suppresses prolactin (PRL) secretion
CNS (basal ganglia): Mimics dopaminergic activity → used in Parkinson's disease
Hypothalamus/circadian axis: Modulates central dopaminergic tone → improves glycemic control (Cycloset formulation)

Clinical Indications

Indication	Notes
Hyperprolactinemia / Prolactinoma	First-line therapy; shrinks prolactin-secreting tumors
Galactorrhea	Due to suppression of PRL
Female infertility (from hyperprolactinemia)	Restores ovulatory cycles
Acromegaly	Second-line adjunct; suppresses GH in some cases
Parkinson's disease	Dopamine agonist for motor symptom management
Type 2 Diabetes Mellitus	Cycloset formulation; primarily reduces postprandial glucose (PPG)
Neuroleptic Malignant Syndrome (NMS)	Off-label dopaminergic rescue therapy

Dosing

Hyperprolactinemia / Prolactinoma

(Harrison's, p. 10614)

Start: 0.625–1.25 mg at bedtime with a snack (to minimize GI/orthostatic side effects)
Titrate gradually upward
Maintenance: Most patients controlled at ≤7.5 mg/day (typical: 2.5 mg three times daily)
Short-acting → preferred when pregnancy is desired (can be stopped promptly once pregnancy is confirmed)

Parkinson's Disease

Start low (1.25 mg twice daily), titrate over weeks
Usual range: 10–40 mg/day in divided doses

Type 2 Diabetes (Cycloset)

0.8 mg tablets taken within 2 hours of waking
Titrate weekly up to 1.6–4.8 mg/day
Primarily lowers postprandial glucose with low hypoglycemia risk

Adverse Effects

Common

Nausea, vomiting (most common — mitigated by taking with food, starting at low dose)
Orthostatic hypotension, dizziness
Headache
Nasal congestion

CNS/Neuropsychiatric

Hallucinations, confusion (especially at high doses used for Parkinson's)
Impulse control disorders (gambling, hypersexuality — class effect of dopamine agonists)
Somnolence, sudden sleep attacks

Serious / Rare

Ergot-related vasospasm (Raynaud's phenomenon, digital ischemia)
Pleuropulmonary fibrosis and retroperitoneal fibrosis (with chronic high-dose use)
Cardiac valvulopathy (less than cabergoline, but possible)
Stroke/seizure — reported postpartum with high doses (avoid in postpartum hypertension)

Contraindications

Uncontrolled hypertension
Hypersensitivity to ergot alkaloids
Syncopal migraine
Postpartum period (if hypertension, eclampsia, or seizures present)
Breastfeeding (suppresses lactation — intentional or not)

Bromocriptine vs. Cabergoline

Feature	Bromocriptine	Cabergoline
Half-life	Short (~3–7 hrs)	Long (~65 hrs)
Dosing	TID	Once or twice weekly
Preferred in pregnancy	Yes (more safety data)	Less preferred
Tolerability	Lower	Better (fewer GI/orthostatic SE)
Fibrosis risk	Lower	Slightly higher (high doses)
Cost	Lower	Higher

Key Points

Bromocriptine is the preferred dopamine agonist when fertility is desired, due to its short action and extensive pregnancy safety data.
In prolactinomas, it both normalizes PRL levels and reduces tumor size.
The Cycloset formulation for T2DM works via a distinct central mechanism and does not cause hypoglycemia as monotherapy.
Always start low and titrate slowly to minimize nausea and orthostatic hypotension.

Can use bromocriptin e in central fever

search_medical_text

bromocriptine central fever neurogenic fever treatment

Harrison's Principles of Internal Medicine, Twenty First Edition

Page 647

search_medical_text

central fever pathophysiology management hypothalamic fever

Harrison's Principles of Internal Medicine, Twenty First Edition

Page 637

GradeResponse

Yes, bromocriptine can be used in central (neurogenic) fever, though it is considered an off-label, second-line option used when conventional antipyretics fail.

Central Fever — Quick Overview

Central (neurogenic) fever results from direct disruption of the hypothalamic thermoregulatory center, not from pyrogen-mediated elevation of the set point. Common causes:

Traumatic brain injury (TBI)
Subarachnoid hemorrhage (SAH)
Intracranial hemorrhage / stroke
Hypothalamic tumors or surgery
Severe hypoxic-ischemic encephalopathy

Key feature: does not respond reliably to NSAIDs or acetaminophen, because the mechanism is structural/autonomic, not prostaglandin-mediated (Harrison's, p. 637).

Role of Bromocriptine

The rationale is dopaminergic:

Hypothalamic thermoregulation is partly modulated by dopaminergic pathways
In central fever (and in conditions like Paroxysmal Sympathetic Hyperactivity / sympathetic storming after TBI), there is dysregulated autonomic/hypothalamic activity
Bromocriptine, as a D2 agonist, dampens hypothalamic hyperactivity and reduces sympathetic outflow → lowers temperature

It is most commonly used in two specific contexts:

1. Paroxysmal Sympathetic Hyperactivity (PSH) after TBI/SAH

PSH causes episodic fever, tachycardia, hypertension, diaphoresis, posturing
Bromocriptine 2.5–7.5 mg/day (in divided doses) is a recognized agent in the PSH management bundle alongside propranolol, opioids, and clonidine

2. Neuroleptic Malignant Syndrome (NMS)

NMS is essentially central dopamine blockade → hyperthermia + rigidity
Bromocriptine 2.5–10 mg TID directly reverses the dopamine deficit, making it one of the primary pharmacological treatments

Practical Use in Central Fever

Aspect	Detail
Dose	Start 2.5 mg BID–TID, titrate to effect
Route	Oral or via NG tube (no IV formulation)
Onset	Hours to days
Monitoring	BP (hypotension), mental status, GI tolerance
Combination	Often used with cooling blankets, propranolol, or clonidine

Limitations

Not a first-line agent for central fever in general — cooling blankets and acetaminophen are tried first
Evidence is largely from case series and small studies, not RCTs
Not effective if the fever has an infectious or inflammatory cause — always rule out infection before attributing fever to a central origin
Cabergoline is sometimes preferred in NMS due to better tolerability, but bromocriptine has more established use

Bottom line: Bromocriptine is a reasonable and used option for central fever — particularly in PSH after brain injury and in NMS — when the mechanism is dopaminergic dysregulation. It is not effective for standard infectious/inflammatory fever.

This is a shared conversation. Sign in to Orris to start your own chat.